Rituximab in B-cell disorders other than non-Hodgkin's lymphoma

Anti-Cancer Drugs

Volumn 13, Issue SUPPL. 2, 2002, Pages

  Bosly, Andre ^a   Keating, Michael J ^b   Stasi, Roberto ^c   Bradstock, Ken ^d  

^a Cliniques Universitaires   (Belgium)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c REGINA APOSTOLORUM HOSPITAL   (Italy)

^d WESTMEAD HOSPITAL   (Australia)

Author keywords

Chronic lymphocytic leukemia; Cold agglutinin disease; Idiopathic thrombocytopenic purpura; Rituximab; Waldenstr m's macroglobulinemia

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE; RITUXIMAB;

ADULT; AUTOIMMUNE HEMOLYTIC ANEMIA; B CELL LYMPHOMA; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HAIRY CELL LEUKEMIA; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LYMPHOPROLIFERATIVE DISEASE; MALE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SIDE EFFECT; WALDENSTROEM MACROGLOBULINEMIA;

EID: 0036877903     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200211002-00005     Document Type: Conference Paper

References (43)

1. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435-45.
2. Shan D, Ledbetter JA, Press OW. Signaling events involved in anti-CD20-induced apoptosis of malignant human B-cells. Cancer Immunol Immunother 2000; 48: 673-83.
3. Demidem A, Lam T, Alas S, Hariharann K, Hanna N, Bonavida B. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997; 12: 177-86.
4. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: haft of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825-33.
5. Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17: 268-76.
6. Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998; 92: 1927-32.
7. Coiffier B, Lepage E, Herbrecht R, et al. MabThera (rituximab) plus CHOP is superior to CHOP alone in elderly patients with diffuse large B-cell lymphoma (DLCL): interim results of a randomized GELA trial. Blood 2000; 96(suppl 1): 223a.
8. Vose JM, Link BK, Grossbard ML, et al. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 2001; 19: 389-97.
9. Haioun C, Delfau-Larue MH, Beaujean F. Efficiency of in vivo purging with rituximab followed by high-dose therapy (HDT) with autologous peripheral blood stem cell transplantation (PBSCT) in B-cell non-Hodgkin's lymphomas (NHL). A single institution study. Blood 2000; 96: 384a.
10. Buckstein R, Imrie D, Spaner J. High frequency of molecular remissions associated with rituxan or IFN immunotherapy following ASCT for follicular NHL. Blood 2000; 96(suppl 1): 791a.
11. Dighiero G, Binet JL. Chronic lymphocytic leukemia. Hematol Cell Ther 1996; 38(suppl 2): S41-61.
12. Huh YO, Keating MJ, Saffer HL, Jilani I, Lerner S, Albitar M. Higher levels of surface CD20 expression on circulating lymphocytes compared with bone marrow and lymph nodes in B-cell chronic lymphocytic leukemia. Am J Clin Pathol 2001; 116: 437-43.
13. Keating MJ. Progress in CLL, chemotherapy, antibodies and transplantation. Biomed Pharmacother 2001; 55: 524-8.
14. Byrd JC, Murphy T, Howard RS, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001; 19: 2153-64.
15. Huhn D, von Schilling C, Wilhelm M, et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 2001; 98: 1326-31.
16. O'Brien SM, Kantarjian H, Thomas DA, et al. Rituximab dose-escalation trial in chronic lymphocytic leukaemia. J Clin Oncol 2001; 19: 2165-70.
17. Berinstein NL, Grillo-Lopez AJ, White CA, et al. Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1998; 9: 995-1001.
18. Wierda W, O'Brien S, Albitar M, et al. Combined fludarabine, cyclophosphamide, and rituximab achieves a high complete remission rate as initial treatment for chronic lymphocytic leukemia. Blood 2001; 98: abstract 3210.
19. Cook RC, Connors JM, Gascoyne RD, Fradet G, Levy RD. Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation. Lancet 1999; 354: 1698-9.
20. Zilz ND, Olson LJ, McGregor CG. Treatment of post-transplant lymphoproliferative disorder with monoclonal CD20 antibody (rituximab) after heart transplantation. J Heart Lung Transplant 2001; 20: 770-2.
21. Zompi S, Tulliez M, Conti F, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with clonal lymphoproliferative disorders after orthotopic liver transplantation: a report of three cases. J Hepatol 2000; 32: 521-7.
22. O'Dwyer ME, Launder T, Rabkin JM, Nichols CR. Successful treatment of aggressive post transplant lymphoproliferative disorder using rituximab. Leuk Lymphoma 2000; 39: 411-9.
23. Milpied N, Vasseur B, Parquet N, et al. Humanized anti-CD20 monoclonal antibody (rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol 2000; 11(suppl 1): 113-6.
24. Faye A, Quartier P, Reguerre Y, et al. Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children. Br J Haematol 2001; 115: 112-8.
25. Stasi R, Stipa E, Masi M, et al. Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am J Med 1995; 98: 436-42.
26. Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001; 98: 952-7.
27. Witzig TE, Timm M, Larson D, Therneau T, Greipp PR. Measurement of apoptosis and proliferation of bone marrow plasma cells in patients with plasma cell proliferative disorders. Br J Haematol 1999; 104: 131-7.
28. Kastrinakis NG, Gorgoulis VG, Foukas PG, Dimopoulos MA, Kittas C. Molecular aspects of multiple myeloma. Ann Oncol 2000; 11: 1217-28.
29. Gertz MA, Fonseca R, Rajkumar SV. Waldenström's macroglobulinemia. Oncologist 2000; 5: 63-7.
30. Treon SP, Shima Y, Grossbard ML, et al. Treatment of multiple myeloma by antibody mediated immunotherapy and induction of myeloma selective antigens. Ann Oncol 2000; 11(suppl 1): 107-11.
31. Byrd JC, White CA, Link B, et al. Rituximab therapy in Waldenstrom's macroglobulinemia: preliminary evidence of clinical activity. Ann Oncol 1999; 10: 1525-7.
32. Treon SP, Shima Y, Preffer FI, et al. Interferon-γ induces CD20 expression on multiple myeloma patient and healthy plasma cells and augments binding of rituximab. Ann Oncol 1999; 10(suppl): 34.
33. Treon SP, Agus DB, Link B, et al. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenström's macroglobulinemia. J Immunother 2001; 24: 272-9.
34. Treon SP, Shima Y, Preffer FI, et al. Treatment of plasma cell dyscrasias by antibody-mediated immunotherapy. Semin Oncol 1999; 26(5 suppl 14): 97-106.
35. Efremov DG, Ivanovski M, Burrone OR. The pathologic significance of the immunoglobulins expressed by chronic lymphocytic leukemia B-cells in the development of autoimmune hemolytic anemia. Leuk Lymphoma 1998; 28: 285-93.
36. Bauduer F. Rituximab: a very efficient therapy in cold agglutinins and refractory autoimmune haemolytic anaemia associated with CD20-positive, low-grade non-Hodgkin's lymphoma. Br J Haematol 2001; 112: 1085-6.
37. Lee EJ, Kueck B. Rituxan in the treatment of cold agglutinin disease. Blood 1998; 92: 3490-1.
38. Layios N, Van Den Neste E, Jost E, Deneys V, Scheiff JM, Ferrant A. Remission of severe cold agglutinin disease after rituximab therapy. Leukemia 2001; 15: 187-8.
39. Zinzani PL, Ascani S, Piccaluga PP, Bendandi M, Pileri S, Tura S. Efficacy of rituximab in hairy cell leukemia treatment. J Clin Oncol 2000; 18: 3875-7.
40. Dearden CE, Matutes E, Hilditch BL, Swansbury GJ, Catovsky D. Long-term follow-up of patients with hairy cell leukaemia after treatment with pentostatin or cladribine. Br J Haematol 1999; 106: 515-9.
41. Hagberg H. Chimeric monoclonal anti-CD20 antibody (rituximab) - an effective treatment for a patient with relapsing hairy cell leukaemia. Medical Oncol 1999; 16: 221-2.
42. Hagberg H, Lundholm L. Rituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukemia. Br J Haematol 2001; 115: 609-11.
43. Keating M, O'Brien S, Lerner S, et al. Combination chemo-antibody therapy with fiudarabine (F), cyclophosphamide (C) and rituximab (R) achieves a high CR rate in previously untreated chronic lymphocytic leukemia (CLL). Blood 2000; 96: abstract 2214.